Skip to main content
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1983 Jul;36(7):804–807. doi: 10.1136/jcp.36.7.804

Plasma spermidine concentrations as early indication of response to therapy in human myeloma.

O A Van Dobbenburgh, B Houwen, H Jurjens, J Marrink, M R Halie, H O Nieweg
PMCID: PMC498392  PMID: 6863572

Abstract

Eighteen patients with melphalan refractory myeloma were treated with vindesine and prednisone. Plasma spermidine concentrations were measured by radioimmunoassay before and after a single vindesine injection. Seven patients showed a significant rise of plasma spermidine after vindesine and five of these showed a clinical response on further evaluation. Of the 11 patients who did not show raised spermidine concentrations, 10 did not respond to the therapy. The correlation between clinical response/rise of spermidine and between non-response/no rise of spermidine was statistically significant (p less than 0.05). Pretreatment spermidine concentrations did not distinguish those who responded to treatment nor did they differ in patients and controls.

Full text

PDF
804

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Bonnet J., Gehan E., Haut A., Hewlett J., Lane M., Monto R., Wilson H. Combination chemotherapy for multiple myeloma. Cancer. 1972 Aug;30(2):382–389. doi: 10.1002/1097-0142(197208)30:2<382::aid-cncr2820300213>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  2. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  3. Durie B. G., Salmon S. E., Russell D. H. Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res. 1977 Jan;37(1):214–221. [PubMed] [Google Scholar]
  4. Durie B. G. Staging and kinetics of multiple myeloma. Clin Haematol. 1982 Feb;11(1):3–18. [PubMed] [Google Scholar]
  5. Hill B. T., Whelan R. D. Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro. Cancer Treat Rev. 1980 Sep;7 (Suppl 1):5–15. doi: 10.1016/s0305-7372(80)80002-8. [DOI] [PubMed] [Google Scholar]
  6. Houwen B., Ockhuizen T., Marrink J., Nieweg H. O. Vindesine therapy in melphalan-resistant multiple myeloma. Eur J Cancer. 1981 Feb;17(2):227–232. doi: 10.1016/0014-2964(81)90040-2. [DOI] [PubMed] [Google Scholar]
  7. Jänne J., Pösö H., Raina A. Polyamines in rapid growth and cancer. Biochim Biophys Acta. 1978 Apr 6;473(3-4):241–293. doi: 10.1016/0304-419x(78)90015-x. [DOI] [PubMed] [Google Scholar]
  8. Russell D. H., Durie B. G., Salmon S. E. Polyamines as predictors of success and failure in cancer chemotherapy. Lancet. 1975 Oct 25;2(7939):797–799. doi: 10.1016/s0140-6736(75)80009-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES